
Francesc Xavier Bosch JosÉ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5828182/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS ONE, 2016, 11, e0147029.	1.1	102
2	Role of Human Papillomavirus in Penile Carcinomas Worldwide. European Urology, 2016, 69, 953-961.	0.9	210
3	Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950–1999. Cancer Epidemiology, 2016, 40, 173-178.	0.8	1
4	Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine, 2016, 34, 757-761.	1.7	31
5	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	12.5	154
6	Screening of cervical cancer in Catalonia 2006–2012. Ecancermedicalscience, 2015, 9, 532.	0.6	7
7	Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. BioMed Research International, 2015, 2015, 1-9.	0.9	14
8	Training in the prevention of cervical cancer: advantages of e-learning. Ecancermedicalscience, 2015, 9, 580.	0.6	6
9	Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) ASO4-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Vaccine Journal, 2015, 22, 361-373.	3.2	89
10	Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM. Clinical Microbiology and Infection, 2015, 21, 605.e11-605.e19.	2.8	18
11	Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. International Journal of Cancer, 2015, 136, 98-107.	2.3	296
12	Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiology, 2014, 38, 748-756.	0.8	37
13	Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. Journal of Infectious Diseases, 2014, 210, 517-534.	1.9	45
14	Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. International Journal of Cancer, 2014, 135, 88-95.	2.3	48
15	Pathogenic role of the eight probably/possibly carcinogenic <scp>HPV</scp> types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. Journal of Pathology, 2014, 234, 441-451.	2.1	119
16	Phylogenetically related, clinically different: human papillomaviruses 6 and 11 variants distribution in genital warts and in laryngeal papillomatosis. Clinical Microbiology and Infection, 2014, 20, O406-O413.	2.8	9
17	Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infectious Diseases, 2014, 14, 551.	1.3	32
18	Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study. BMC Infectious Diseases, 2014, 14, 75.	1.3	42

#	Article	IF	CITATIONS
19	Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort. International Journal of Cancer, 2014, 135, 440-452.	2.3	44
20	HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncology, The, 2014, 15, 1319-1331.	5.1	581
21	Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples. European Journal of Cancer, 2014, 50, 2846-2854.	1.3	140
22	Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina. Cancer Epidemiology, 2014, 38, 504-510.	0.8	8
23	Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer, 2014, 14, 574.	1.1	15
24	Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. International Journal of Cancer, 2014, 135, 453-466.	2.3	161
25	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	1.1	137
26	The role of human papillomavirus in head and neck cancer in Senegal. Infectious Agents and Cancer, 2013, 8, 14.	1.2	36
27	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World Journal of Urology, 2013, 31, 861-867.	1.2	110
28	Screening for Cervical Cancer and Human Papillomavirus Vaccination in Israel: Recommendations. Vaccine, 2013, 31, 158-160.	1.7	2
29	Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer, 2013, 49, 3450-3461.	1.3	320
30	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, I1-I31.	1.7	261
31	The Path to Eliminate Cervical Cancer in the World and the Challenges of Professional Education. Vaccine, 2013, 31, xi-xii.	1.7	4
32	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	1.7	272
33	Recommendations for Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F73-F74.	1.7	29
34	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
35	Recommendations for Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine, 2013, 31, H80-H82.	1.7	15
36	The Path to Eliminate Cervical Cancer in the World and the Challenges of Professional Education. Vaccine, 2013, 31, xi-xii.	1.7	0

#	Article	IF	CITATIONS
37	Extended Middle East and North Africa: Summary Recommendations for the Prevention of Human Papillomavirus Infections and Related Cancers Including Cervical Cancer. Vaccine, 2013, 31, G78-G79.	1.7	2
38	Poor Prognosis Associated With Human Papillomavirus α7ÂGenotypes in Cervical Carcinoma Cannot Be ExplainedÂby Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2013, 85, e223-e229.	0.4	9
39	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33
40	The Path to Eliminate Cervical Cancer in the World and the Challenges of Professional Education. Vaccine, 2013, 31, ix-x.	1.7	0
41	Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infectious Diseases, 2013, 13, 18.	1.3	19
42	Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology, 2013, 63, 287-292.	1.6	23
43	Differential presence of Papillomavirus variants in cervical cancer: An analysis for HPV33, HPV45 and HPV58. Infection, Genetics and Evolution, 2013, 13, 96-104.	1.0	17
44	Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1313-1318.	1.1	38
45	Coverage of Cervical Cancer Screening in Catalonia for the Period 2008–2011 among Immigrants and Spanish-Born Women. Frontiers in Oncology, 2013, 3, 297.	1.3	18
46	Using HPV prevalence to predict cervical cancer incidence. International Journal of Cancer, 2013, 132, 1895-1900.	2.3	26
47	Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS ONE, 2013, 8, e79260.	1.1	101
48	Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. Journal of Virology, 2012, 86, 6855-6861.	1.5	136
49	Male Circumcision and Genital Human Papillomavirus. Sexually Transmitted Diseases, 2012, 39, 104-113.	0.8	102
50	Basaloid Squamous Cell Carcinoma of the Penis With Papillary Features. American Journal of Surgical Pathology, 2012, 36, 869-875.	2.1	40
51	Intrauterine Device Use, Cervical Infection With Human Papillomavirus, and Risk of Cervical Cancer. Obstetrical and Gynecological Survey, 2012, 67, 353-355.	0.2	Ο
52	Overall efficacy of HPV-16/18 ASO4-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 89-99.	5.1	584
53	Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 100-110.	5.1	432
54	Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in in invasive cervical cancer. Journal of Pathology, 2012, 228, 534-543.	2.1	47

#	Article	IF	CITATIONS
55	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 2012, 127, 440-450.	0.6	55
56	The Path to Eliminate Cervical Cancer in the World and the Challenges of Professional Education. Vaccine, 2012, 30, xi-xii.	1.7	4
57	Typeâ€specific human papillomavirus distribution in invasive cervical carcinomas in Paraguay. A study of 432 cases. Journal of Medical Virology, 2012, 84, 1628-1635.	2.5	17
58	Human papillomavirus distribution in invasive cervical carcinoma in sub‧aharan Africa: could HIV explain the differences?. Tropical Medicine and International Health, 2012, 17, 1432-1440.	1.0	32
59	Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infectious Diseases, 2012, 12, 145.	1.3	26
60	Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain. BMC Infectious Diseases, 2012, 12, 25.	1.3	15
61	Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer, 2012, 7, 38.	1.2	232
62	GAVI Report. Vaccine, 2012, 30, D1-D83.	1.7	59
63	Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. Vaccine, 2012, 30, F1-F11.	1.7	40
64	Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study. Journal of Medical Virology, 2012, 84, 947-956.	2.5	77
65	Time since first sexual intercourse and the risk of cervical cancer. International Journal of Cancer, 2012, 130, 2638-2644.	2.3	122
66	Efficacy of the human papillomavirus (HPV)â€16/18 ASO4â€adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPVâ€16/18. International Journal of Cancer, 2012, 131, 106-116.	2.3	109
67	Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecologic Oncology, 2012, 124, 512-517.	0.6	27
68	Clinical evaluation of polymerase chain reaction reverse hybridization assay for detection and identification of human papillomavirus type 16 variants. Journal of Clinical Virology, 2011, 51, 165-169.	1.6	18
69	HPV types in early-onset cervical cancer – Authors' reply. Lancet Oncology, The, 2011, 12, 117-118.	5.1	2
70	Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncology, The, 2011, 12, 1023-1031.	5.1	98
71	Value of p16INK4a in the Pathology of Invasive Penile Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2011, 35, 253-261.	2.1	104
72	The Prospects of HPV Vaccination in Cervical Cancer Prevention: Results of a New Independent Trial. Cancer Discovery, 2011, 1, 377-380.	7.7	8

#	Article	IF	CITATIONS
73	Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infectious Agents and Cancer, 2011, 6, 23.	1.2	9
74	Dietary factors and <i>in situ</i> and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. International Journal of Cancer, 2011, 129, 449-459.	2.3	51
75	Adenocarcinoma <i>in situ</i> and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. International Journal of Cancer, 2011, 128, 1344-1353.	2.3	28
76	Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opinion on Pharmacotherapy, 2011, 12, 2189-2204.	0.9	32
77	Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2532-2540.	1.1	36
78	European Consensus Statement on "HPV Vaccination and Colposcopy". Journal of Lower Genital Tract Disease, 2011, 15, 309-315.	0.9	7
79	Smoking and Passive Smoking in Cervical Cancer Risk: Pooled Analysis of Couples from the IARC Multicentric Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1379-1390.	1.1	64
80	Distinctive Association of p16INK4a Overexpression With Penile Intraepithelial Neoplasia Depicting Warty and/or Basaloid Features: A Study of 141 Cases Evaluating a New Nomenclature. American Journal of Surgical Pathology, 2010, 34, 385-392.	2.1	88
81	Human Papilloma Virus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer, 2010, 10, 259.	1.1	33
82	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. Journal of the National Cancer Institute, 2010, 102, 325-339.	3.0	493
83	Cost-effectiveness of human papillomavirus vaccination and screening in Spain. European Journal of Cancer, 2010, 46, 2973-2985.	1.3	38
84	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology, The, 2010, 11, 1048-1056.	5.1	2,093
85	Cervical Human Papillomavirus Prevalence in 5 Continents: Metaâ€Analysis of 1 Million Women with Normal Cytological Findings. Journal of Infectious Diseases, 2010, 202, 1789-1799.	1.9	1,156
86	Broad-Spectrum Human Papillomavirus Vaccines: New Horizons but One Step at a Time. Journal of the National Cancer Institute, 2009, 101, 771-773.	3.0	9
87	Epigenetic Silencing of Interferon-κ in Human Papillomavirus Type 16–Positive Cells. Cancer Research, 2009, 69, 8718-8725.	0.4	109
88	Differences in the risk of cervical cancer and human papillomavirus infection by education level. British Journal of Cancer, 2009, 101, 865-870.	2.9	65
89	Vaccineâ€related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. International Journal of Cancer, 2008, 122, 1901-1904.	2.3	46
90	Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infectious Diseases, 2008, 8, 85.	1.3	32

#	Article	IF	CITATIONS
91	Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer, 2008, 99, 230-238.	2.9	111
92	The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. Journal of Hepatology, 2008, 49, 233-242.	1.8	60
93	Is viral status needed before vaccination?. Vaccine, 2008, 26, A12-A15.	1.7	12
94	Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine, 2008, 26, L96-L107.	1.7	44
95	Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine, 2008, 26, K1-K16.	1.7	658
96	Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine, 2008, 26, F29-F45.	1.7	42
97	Recommendations for Cervical Cancer Prevention in Asia Pacific. Vaccine, 2008, 26, M89-M98.	1.7	41
98	Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions. Vaccine, 2008, 26, K17-K28.	1.7	297
99	A scientific response to prevent cervical cancer in the world. Vaccine, 2008, 26, v-vi.	1.7	3
100	HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 2008, 26, 6844-6851.	1.7	168
101	Age at sexual initiation and number of sexual partners in the female Spanish population. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 140, 234-240.	0.5	52
102	HPV Types 16, 18, 45 and 31: The Most Important Oncogenic HPV Types Worldwide. International Journal of Infectious Diseases, 2008, 12, e23.	1.5	0
103	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research, 2008, 68, 10178-10186.	0.4	67
104	HPV and cervical cancer: screening or vaccination?. British Journal of Cancer, 2008, 98, 15-21.	2.9	77
105	Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. European Journal of Public Health, 2008, 18, 674-680.	0.1	16
106	Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions. Vaccine Journal, 2008, 15, 172-175.	3.2	11
107	HPV vaccines and cervical cancer. Annals of Oncology, 2008, 19, v48-v51.	0.6	11

Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types) Tj ETQq0 0 0 rg $\frac{BT}{28}$ /Overlock 10 Tf 50

#	Article	IF	CITATIONS
109	Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection. Journal of Infectious Diseases, 2007, 196, 1438-1446.	1.9	167
110	WAERS: An application for web-Assisted estimation of relative survival. Informatics for Health and Social Care, 2007, 32, 169-175.	1.0	9
111	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine, 2007, 25, 6257-6270.	1.7	139
112	Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, The, 2007, 369, 2161-2170.	6.3	1,153
113	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 453-459.	4.6	1,277
114	Cervical Infection With Chlamydia trachomatis and Neisseria gonorrhoeae in Women From Ten Areas in Four Continents. Sexually Transmitted Diseases, 2007, 34, 563-569.	0.8	42
115	HPV and circumcision: A biased, inaccurate and misleading meta-analysis. Journal of Infection, 2007, 55, 91-93.	1.7	39
116	Type-Specific Seroprevalence of Herpes Simplex Virus Type 2 and Associated Risk Factors in Middle-Aged Women From 6 Countries: The IARC Multicentric Study. Sexually Transmitted Diseases, 2007, 34, 1019-1024.	0.8	23
117	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncology, The, 2006, 7, 27-38.	5.1	345
118	CHAPTER 2 The epidemiology of human papillomavirus infection and its association with cervical cancer. International Journal of Gynecology and Obstetrics, 2006, 94, S8-S21.	1.0	64
119	Preface. Vaccine, 2006, 24, v-vi.	1.7	6
120	Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine, 2006, 24, S242-S249.	1.7	19
121	Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine, 2006, 24, S251-S261.	1.7	44
122	Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. International Journal of Cancer, 2006, 119, 687-694.	2.3	37
123	Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer, 2006, 119, 2677-2684.	2.3	332
124	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. Journal of the National Cancer Institute, 2006, 98, 303-315.	3.0	568
125	Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecologic Oncology, 2005, 96, 714-720.	0.6	36
126	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. International lournal of Cancer, 2005, 115, 329-332.	2.3	59

#	Article	IF	CITATIONS
127	The role of diet and nutrition in cervical carcinogenesis: A review of recent evidence. International Journal of Cancer, 2005, 117, 629-637.	2.3	128
128	Chlamydia trachomatis Infection in Female Partners of Circumcised and Uncircumcised Adult Men. American Journal of Epidemiology, 2005, 162, 907-916.	1.6	79
129	Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, The, 2005, 366, 991-998.	6.3	924
130	The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. International Journal of Cancer, 2004, 108, 741-749.	2.3	219
131	Role of hepatitis C virus infection in malignant lymphoma in Spain. International Journal of Cancer, 2004, 111, 81-85.	2.3	43
132	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. International Journal of Cancer, 2004, 111, 278-285.	2.3	912
133	Chlamydia trachomatisand invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. International Journal of Cancer, 2004, 111, 431-439.	2.3	218
134	Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 2004, 127, S5-S16.	0.6	2,193
135	Concordance of Prevalence of Human Papillomavirus DNA in Anogenital and Oral Infections in a High-Risk Population. Journal of Clinical Microbiology, 2004, 42, 1330-1332.	1.8	84
136	Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980???1997 in Catalonia, Spain. European Journal of Gastroenterology and Hepatology, 2004, 16, 865-872.	0.8	15
137	The Etiology of Squamous Cell Cervical Cancer. Cancer Prevention, Cancer Causes, 2004, , 191-216.	0.3	2
138	Prevalence ofBRCA1andBRCA2germline mutations in young breast cancer patients: A population-based study. International Journal of Cancer, 2003, 106, 588-593.	2.3	90
139	Can screening for cervical cancer be improved, especially in developing countries?. International Journal of Cancer, 2003, 107, 337-340.	2.3	25
140	Clearance of HPV infection in middle aged men and women after 9 years' follow up. Sexually Transmitted Infections, 2003, 79, 348-348.	0.8	13
141	Lifetime body mass index and risk of oral cavity and oropharyngeal cancer by smoking and drinking habits. British Journal of Cancer, 2003, 89, 1667-1671.	2.9	30
142	Oral and oropharyngeal cancer in Spain: influence of dietary patterns. European Journal of Cancer Prevention, 2003, 12, 49-56.	0.6	81
143	Evidence forChlamydia trachomatisas a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer in Brazil and the Philippines. Journal of Infectious Diseases, 2002, 185, 324-331.	1.9	210
144	Prevalence and determinants of human papillomavirus genital infection in men. British Journal of Cancer, 2002, 86, 705-711.	2.9	165

#	Article	IF	CITATIONS
145	Risk factors of invasive cervical cancer in Mali. International Journal of Epidemiology, 2002, 31, 202-209.	0.9	154
146	Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet, The, 2002, 359, 1085-1092.	6.3	561
147	Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet, The, 2002, 359, 1093-1101.	6.3	482
148	The viral etiology of cervical cancer. Virus Research, 2002, 89, 183-190.	1.1	169
149	Environmental co-factors in HPV carcinogenesis. Virus Research, 2002, 89, 191-199.	1.1	238
150	Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. International Journal of Cancer, 2002, 98, 155-158.	2.3	92
151	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. New England Journal of Medicine, 2002, 346, 1105-1112.	13.9	707
152	Human papillomavirus genotypes in rural Mozambique. Lancet, The, 2001, 358, 1429-1430.	6.3	114
153	Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Middle-Age Women in Brazil and the Philippines. Sexually Transmitted Diseases, 2001, 28, 187-194.	0.8	42
154	Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes. Journal of Clinical Microbiology, 2001, 39, 4344-4348.	1.8	51
155	Re: Cervical Carcinoma and Human Papillomavirus: On the Road to Preventing a Major Human Cancer. Journal of the National Cancer Institute, 2001, 93, 1349-1350.	3.0	12
156	International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. International Journal of Cancer, 2000, 86, 429-435.	2.3	224
157	Epidemiology of Primary Liver Cancer. Seminars in Liver Disease, 1999, 19, 271-285.	1.8	852
158	PUBLIC HEALTH:Reducing Liver CancerGlobal Control of Aflatoxin. Science, 1999, 286, 2453-2454.	6.0	215
159	Screening for Genital Human Papillomavirus. Diagnostic Molecular Pathology, 1999, 8, 26-31.	2.1	18
160	The viral origin of cervical cancer in Rabat, Morocco. , 1998, 75, 546-554.		126
161	Causes of Cervical Cancer in the Philippines: a Case-Control Study. Journal of the National Cancer Institute, 1998, 90, 43-49.	3.0	161
162	Risk Factors for Cervical Cancer in Thailand: a Case-Control Study. Journal of the National Cancer Institute, 1998, 90, 50-57.	3.0	179

#	Article	IF	CITATIONS
163	Human papillomavirus and other risk factors for cervical cancer. Biomedicine and Pharmacotherapy, 1997, 51, 268-275.	2.5	35
164	Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention. Salud Publica De Mexico, 1997, 39, 274-282.	0.1	52
165	Socioeconomic differences in cervical cancer: two case-control studies in Colombia and Spain American Journal of Public Health, 1996, 86, 1532-1538.	1.5	37
166	A breast cancer case—control study in Girona, Spain. Endocrine, familial and lifestyle factors. European Journal of Cancer Prevention, 1996, 5, 329-335.	0.6	18
167	Difficulty in Elucidating the Male Role in Cervical Cancer in Colombia, a High-Risk Area for the Disease. Journal of the National Cancer Institute, 1996, 88, 1068-1075.	3.0	69
168	Male Sexual Behavior and Human Papillomavirus DNA: Key Risk Factors for Cervical Cancer in Spain. Journal of the National Cancer Institute, 1996, 88, 1060-1067.	3.0	209
169	Cervical cancer and herpes simplex virus type 2: Case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. International Journal of Cancer, 1995, 60, 438-442.	2.3	34
170	Inter-observer variation in cytological and histological diagnoses of cervical neoplasia and its epidemiologic implication. Journal of Clinical Epidemiology, 1995, 48, 1167-1174.	2.4	24
171	Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. Journal of the National Cancer Institute, 1995, 87, 796-802.	3.0	3,021
172	Letters to the Editor. International Journal of Epidemiology, 1994, 23, 1100-1101.	0.9	1
173	Sexually transmitted agents and cervical neoplasia in colombia and Spain. International Journal of Cancer, 1994, 56, 358-363.	2.3	110
174	Human papillomavirus and invasive cervical cancer in Brazil. British Journal of Cancer, 1994, 69, 114-119.	2.9	225
175	Blood transfusion has no effect on colorectal cancer survival. A population-based study. European Journal of Cancer, 1994, 30, 759-764.	1.3	19
176	Diet and colorectal adenomas: A case-control study in majorca. International Journal of Cancer, 1993, 55, 213-219.	2.3	144
177	Serologic response in human papillomavirus-associated invasive cervical cancer. International Journal of Cancer, 1993, 55, 780-784.	2.3	77
178	The causal link between human papillomavirus and invasive cervical cancer: A population-based case-control study in colombia and spain. International Journal of Cancer, 1992, 52, 743-749.	2.3	512
179	Risk factors for cervical cancer in Colombia and Spain. International Journal of Cancer, 1992, 52, 750-758.	2.3	250
180	Nutritional factors in colorectal cancer risk: A case-control study in majorca. International Journal of Cancer, 1991, 49, 161-167.	2.3	247

#	Article	IF	CITATIONS
181	A population-based case-control study of colorectal cancer in majorca. I. Dietary factors. International Journal of Cancer, 1990, 45, 69-76.	2.3	243
182	Cancer incidence correlations: Genital, urinary and some tobacco-related cancers. International Journal of Cancer, 1990, 46, 178-184.	2.3	41
183	Risk factors for hepatocellular carcinoma in catalonia, spain. International Journal of Cancer, 1990, 46, 378-381.	2.3	52
184	Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. British Journal of Cancer, 1988, 57, 1-5.	2.9	194
185	Aflatoxin exposure, hepatitis b virus infection and liver cancer in swaziland. International Journal of Cancer, 1987, 39, 545-553.	2.3	174
186	Studies on the development of the charge heterogeneity of the influenza virus glycoproteins. Archives of Virology, 1985, 83, 311-317.	0.9	4
187	Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial. Cancer, 1985, 56, 2745-2750.	2.0	27
188	Cancer Mortality in Barcelona 1960–1978. International Journal of Epidemiology, 1982, 11, 46-48.	0.9	2